Reuters logo
BRIEF-FDA grants priority review to Merck's application to expand use of Keytruda in hodgkin lymphoma
December 1, 2016 / 12:20 PM / a year ago

BRIEF-FDA grants priority review to Merck's application to expand use of Keytruda in hodgkin lymphoma

Dec 1 (Reuters) - Merck & Co Inc

* FDA grants priority review to supplemental biologics license application (SBLA) for Merck’s Keytruda (Pembrolizumab) in relapsed or refractory classical Hodgkin Lymphoma Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below